

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/934,358	08/21/2001~	Olivier Civelli	90,1092-BBB	7934	
20306 7590 08/14/2003  MCDONNELL BOEHNEN HULBERT & BERGHOFF 300 SOUTH WACKER DRIVE SUITE 3200					
			EXAMINER		
			ULM, JOHN D		
CHICAGO, IL	60606		ART UNIT	PAPER NUMBER	
		•	1646	10	
			DATE MAILED: 08/14/2003	·	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. 09/934,358

Applicant(s)

\_\_\_\_

Civelli et al.

Examiner

John Ulm

Art Unit 1646

	The MAILING DATE of this communication appears	on the cover she	et with the	correspondence address		
	for Reply	•				
THE I - Extens mailing - If the p	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.136 (a). If g date of this communication, period for reply specified above is less than thirty (30) days, a reply within period for reply is specified above, the maximum statutory period will apply	n no event, however, m the statutory minimum o and will expire SIX (6)	ay a reply be ti of thirty (30) d MONTHS from	mely filed after SIX (6) MONTHS from the ays will be considered timely. the mailing date of this communication.		
- Any re	to reply within the set or extended period for reply will, by statute, cause by received by the Office later than three months after the mailing date of patent term adjustment. See 37 CFR 1.704(b).	• •		•		
Status	patent term adjustment. 366 37 GTT 1.70-(b).		•			
1) 💢	Responsive to communication(s) filed on Jun 9, 2	003	*	<del> </del>		
2a) 🗶	This action is <b>FINAL</b> . 2b) ☐ This ac	tion is non-final.				
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under $Ex\ particles$	· ·				
Disposi	tion of Claims					
4) 💢	Claim(s) <u>1-4</u>	· 		is/are pending in the application.		
4	a) Of the above, claim(s)	· ,		_ is/are withdrawn from consideration.		
5) 🗀	Claim(s)	· ·	<u>.</u>	is/are allowed.		
6) 💢	Claim(s) 1-4	· · · · · · · · · · · · · · · · · · ·		is/are rejected.		
7) 🗌	· ·			is/are objected to.		
8) 🗆	Claims	are	subject to	restriction and/or election requirement.		
Applica	ition Papers					
9) 🗀	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/ar	e a) 🗆 accepted	d or b)□ (	objected to by the Examiner.		
	Applicant may not request that any objection to the	drawing(s) be hele	d in abeyar	nce. See 37 CFR 1.85(a).		
11)	The proposed drawing correction filed on	is:	а) 🗆 арр	roved b)□ disapproved by the Examiner		
	If approved, corrected drawings are required in reply	to this Office act	ion	•		
12)	The oath or declaration is objected to by the Exam	niner.	•	,		
Priority	under 35 U.S.C. §§ 119 and 120					
13)	Acknowledgement is made of a claim for foreign p	oriority under 35	U.S.C. §	119(a)-(d) or (f).		
a) 🗆	☐ All b)☐ Some* c)☐ None of:	•				
,	1. $\square$ Certified copies of the priority documents ha	ve been received	i.			
	2. $\square$ Certified copies of the priority documents ha	ve been received	in Applic	ation No		
	<ol> <li>Copies of the certified copies of the priority of application from the International Bure</li> </ol>			ived in this National Stage		
*S	ee the attached detailed Office action for a list of the	ne certified copie	s not rece	ived.		
14) 🗌	Acknowledgement is made of a claim for domestic	c priority under 3	85 U.S.C.	§ 119(e).		
a) [	,	• •				
15) 🗀	Acknowledgement is made of a claim for domestic	priority under 3	35 U.S.C.	§§ 120 and/or 121.		
Attachm	•					
	tice of References Cited (PTO-892)	4) Interview Sum	Ť			
	omination. Disclosure Statement(s) (F10-1443) Paper No(s).	6) Uther:				

Art Unit: 1646

- 1) Claims 1 to 4 are pending in the instant application. Claims 2 and 4 have been amended and claims 5 to 19 have been canceled as requested by Applicant in Paper Number 9, filed 09 June of 2003. The proposed amendments to page 30 at line 4, page 50 at line 13, page 60 at line 4 and page 63 at line 2 contained therein have not been entered because they do not correspond to text present in the specification at the indicated positions.
- 2) Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.
- 3) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 4) Claims 2 and 4 stand rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for those reasons of record in section 7 of Paper Number 8. As stated therein these claims are vague and indefinite because the limitation "hybridizes under high stringency conditions" is conditional and no defining set of conditions are recited in the claims or described in the instant specification. Whereas the instant specification describes specific hybridization conditions on pages 13, 16, 74 and 75, it does not identify any particular set of conditions as "high stringency conditions". Applicant has traversed this rejection on the premise that "the term would be understood by one of ordinary skill in the art". This is not persuasive because there is no single set of hybridization conditions recognized in the art as "high stringency

Page 3

Application/Control Number: 09/934,358

Art Unit: 1646

conditions" and one of skill in the art can not determine if a referenced polynucleotide is included or excluded by this limitation in the absence of a precise definition of this term.

the Wouters et al. publication (Biochem. Pharm. 33(24):4039-4044, 1984) for those reasons of record in section 9 of Paper Number 8. Applicant traverses this rejection on the premise that other species of dopamine receptor may be present in the membrane preparations of Wouters et al. and that there is no evidence of record to support a position that those preparations "homogeneously contain just the D2 dopamine receptor species of the claimed invention". The rejection is maintained because the instant claims encompass any membrane preparation "comprising" the recited receptor protein and the evidence of record clearly supports a conclusion that the preparations of Wouters et al. "comprise" the recited D2 dopamine receptor of the instant claims. Nowhere in these claims can one find a limitation reciting membrane preparations which "homogeneously contain just the D2 dopamine receptor species of the claimed invention". The vector limitations of claim 3 and 4 are not distinguishing because they are product-by-process limitations and the vector recited therein would not be present in the final product.

M.P.E.P. 2113 Product-by-Process Claims

PRODUCT-BY-PROCESS CLAIMS ARE NOT LIMITED TO THE

MANIPULATIONS OF THE RECITED STEPS, ONLY THE STRUCTURE

IMPLIED BY THE STEPS

"[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of

Art Unit: 1646

the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) (citations omitted) (Claim was directed to a novolac color developer. The process of making the developer was allowed. The difference between the inventive process and the prior art was the addition of metal oxide and carboxylic acid as separate ingredients instead of adding the more expensive pre-reacted metal carboxylate. The product-by-process claim was rejected because the end product, in both the prior art and the allowed process, ends up containing metal carboxylate. The fact that the metal carboxylate is not directly added, but is instead produced in-situ does not change the end product.).

The structure implied by the process steps should be considered when assessing the patentability of product-by-process claims over the prior art, especially where the product can only be defined by the process steps by which the product is made, or where the manufacturing process steps would be expected to impart distinctive structural characteristics to the final product. See, e.g., In re Garnero, 412 F.2d 276, 279, 162 USPQ 221, 223 (CCPA 1979) (holding "interbonded by interfusion" to limit structure of the claimed composite and noting that terms such as "welded," "intermixed," "ground in place," "press fitted," and "etched" are capable of construction as structural limitations.)<

ONCE A PRODUCT APPEARING TO BE SUBSTANTIALLY IDENTICAL IS
FOUND AND A 35 U.S.C. 102 /103 REJECTION MADE, THE BURDEN
SHIFTS TO THE APPLICANT TO SHOW AN UNOBVIOUS DIFFERENCE

"The Patent Office bears a lesser burden of proof in making out a case of prima facie obviousness for product-by-process claims because of their peculiar nature" than when a product is claimed in the conventional fashion. In re Fessmann, 489 F.2d 742, 744, 180 USPQ 324, 326 (CCPA 1974). Once the examiner provides a rationale tending to show that the claimed product appears to be the same or similar to that of the prior art, although produced by a different process, the burden shifts to applicant to come forward with evidence establishing an unobvious difference between the claimed product and the prior art product. In re Marosi, 710 F.2d 798, 802, 218 USPQ 289, 292 (Fed. Cir. 1983) (The claims were directed to a zeolite manufactured by mixing together various inorganic materials in solution and heating the resultant gel to form a crystalline metal silicate essentially free of alkali metal. The prior art described a process of making a zeolite which, after ion exchange to remove alkali metal, appeared to be "essentially free of alkali metal." The court upheld the rejection because the applicant had not come forward with any

Art Unit: 1646

evidence that the prior art was not "essentially free of alkali metal" and therefore a different and unobvious product.).

Ex parte Gray, 10 USPQ2d 1922 (Bd. Pat. App. & Inter. 1989) (The prior art disclosed human nerve growth factor (b-NGF) isolated from human placental tissue. The claim was directed to b-NGF produced through genetic engineering techniques. The factor produced seemed to be substantially the same whether isolated from tissue or produced through genetic engineering. While the applicant questioned the purity of the prior art factor, no concrete evidence of an unobvious difference was presented. The Board stated that the dispositive issue is whether the claimed factor exhibits any unexpected properties compared with the factor disclosed by the prior art. The Board further stated that the applicant should have made some comparison between the two factors to establish unexpected properties since the materials appeared to be identical or only slightly different.).

The decision in Ex parte Gray discussed above is particularly relevant to the instant rejection since it is based upon a similar fact situation.

- 6) Applicant's arguments filed 09 June of 2003 have been fully considered but they are not persuasive for those reasons given above.
- 7) THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however,

Art Unit: 1646

will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JOHN ULM PRIMARY EXAMINER GROUP 1800